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Effectiveness and safety of electronically delivered prescribing 
feedback and decision support on antibiotic use for respiratory 
illness in primary care: REDUCE cluster randomised trial 
Martin C Gulliford,1,2 A Toby Prevost,1,2,3 Judith Charlton,1 Dorota Juszczyk,1,2 Jamie Soames,4 
Lisa McDermott,1 Kirin Sultana,4 Mark Wright,4 Robin Fox,5 Alastair D Hay,6 Paul Little,7  
Michael V Moore,7 Lucy Yardley,8,9 Mark Ashworth1
ABSTRACT
OBJECTIVES
To evaluate the effectiveness and safety at population 
scale of electronically delivered prescribing feedback 
and decision support interventions at reducing 
antibiotic prescribing for self limiting respiratory tract 
infections.
DESIGN
Open label, two arm, cluster randomised controlled 
trial.
SETTING
UK general practices in the Clinical Practice Research 
Datalink, randomised between 11 November 2015 
and 9 August 2016, with final follow-up on 9 August 
2017.
PARTICIPANTS
79 general practices (582 675 patient years) 
randomised (1:1) to antimicrobial stewardship (AMS) 
intervention or usual care.
INTERVENTIONS
AMS intervention comprised a brief training webinar, 
automated monthly feedback reports of antibiotic 
prescribing, and electronic decision support 
tools to inform appropriate prescribing over 12 
months. Intervention components were delivered 
electronically, supported by a local practice champion 
nominated for the trial.
MAIN OUTCOME MEASURES
Primary outcome was the rate of antibiotic 
prescriptions for respiratory tract infections 
from electronic health records. Serious bacterial 
complications were evaluated for safety. Analysis 
was by Poisson regression with general practice as a 
random effect, adjusting for covariates. Prespecified 
subgroup analyses by age group were reported.
RESULTS
The trial included 41 AMS practices (323 155 patient 
years) and 38 usual care practices (259 520 patient 
years). Unadjusted and adjusted rate ratios for 
antibiotic prescribing were 0.89 (95% confidence 
interval 0.68 to 1.16) and 0.88 (0.78 to 0.99, P=0.04), 
respectively, with prescribing rates of 98.7 per 1000 
patient years for AMS (31 907 prescriptions) and 
107.6 per 1000 patient years for usual care (27 923 
prescriptions). Antibiotic prescribing was reduced 
most in adults aged 15-84 years (adjusted rate ratio 
0.84, 95% confidence interval 0.75 to 0.95), with one 
antibiotic prescription per year avoided for every 62 
patients (95% confidence interval 40 to 200). There 
was no evidence of effect for children younger than 
15 years (adjusted rate ratio 0.96, 95% confidence 
interval 0.82 to 1.12) or people aged 85 years and 
older (0.97, 0.79 to 1.18); there was also no evidence 
of an increase in serious bacterial complications 
(0.92, 0.74 to 1.13).
CONCLUSIONS
Electronically delivered interventions, integrated into 
practice workflow, result in moderate reductions of 
antibiotic prescribing for respiratory tract infections in 
adults, which are likely to be of importance for public 
health. Antibiotic prescribing to very young or old 
patients requires further evaluation.
TRIAL REGISTRATION
ISRCTN95232781.
Introduction
Overuse of antibiotics in medical practice is 
contributing to the emergence of antimicrobial drug 
resistance. The US Centers for Disease Control estimate 
that each year in the United States, at least two million 
people acquire antibiotic resistant infections and at 
least 23 000 people die as a direct result.1 General 
practice and ambulatory care account for nearly three 
WHAT IS ALREADY KNOWN ON THIS TOPIC
Widespread unnecessary prescribing of antibiotics is contributing to the 
emergence of antimicrobial drug resistance
A systematic review of antimicrobial stewardship interventions suggested 
that single interventions including patient and public education, point-of-care 
testing, audit and feedback, and electronic decision support might be associated 
with reduced antibiotic use
The relevance of previous trials to clinical practice is also unclear because of 
limited reporting of adverse clinical outcomes and lack of detail concerning 
possible effect modifiers, including patient characteristics
WHAT THIS STUDY ADDS
This large UK study used data from electronic health records (EHRs) to 
evaluate effectiveness and safety of an antimicrobial stewardship intervention 
(comprising a training webinar, monthly feedback of antibiotic prescribing data 
from EHRs, and electronic decision support tools)
Overall, the intervention was associated with moderately reduced antibiotic 
prescribing, with no evidence of increased serious bacterial complications; the 
intervention reduced prescribing for adults but not for children or people aged 
85 years or older
Multifaceted interventions, drawing on EHR data, could be scaled up to promote 
effective antimicrobial stewardship in primary care; the needs of very young or 
old patients require further consideration
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quarters of all antibiotic prescribing, with respiratory 
tract infections (RTIs) representing the largest single 
group of indications for antibiotic treatment, including 
cough, acute bronchitis, common colds, otitis media, 
sinusitis, and sore throat.2 Antibiotic treatment 
generally has little if any effect on the severity or 
duration of RTI symptoms, is commonly associated with 
side effects,3 4 and encourages patients to reconsult in 
future episodes.5 Current treatment recommendations 
suggest that a no antibiotic prescribing strategy 
should be agreed on with most patients presenting 
with self limiting RTIs.6 Only limited evidence is 
currently available but a strategy of reduced antibiotic 
prescribing does not appear to compromise patient 
safety in terms of bacterial infections.7 8
A systematic review, updated to 2018, found that 
educational activities aimed at clinicians or patients, 
electronic decision support systems, and audit of 
antibiotic prescribing with feedback of results might be 
used to reduce unnecessary antibiotic prescribing.9 10 
However, the review concluded that it was unclear 
how useful these interventions might be in usual 
clinical practice because of a lack of information about 
possible adverse events, including possible increases 
in bacterial infections.10 Previous studies also lacked 
information about effect modification by patient 
characteristics (such as age, sex, and comorbidity) 
that might influence intervention effectiveness.10 
The review suggested that a strategy of combining 
interventions might hold promise and recommended 
that trials of multifaceted interventions, including 
two or more interventions found to be effective 
individually, should be undertaken.10 Although some 
recent trials have used electronic media to deliver 
interventions,11  12 previous interventions have often 
been resource intensive13 and have not yet shown 
potential to be translated on a wide and sustainable 
scale into routine healthcare. 
The present research focused on low cost 
interventions that can be readily integrated into routine 
practice workflow and scaled up through remote 
delivery using electronic media to a large sample 
of unselected practices. The research developed a 
multicomponent intervention that included a brief 
training webinar for prescribers, followed by monthly 
feedback reports of antibiotic prescribing at RTI 
consultations and decision support tools to inform 
appropriate prescribing. The primary objective of 
the present study (the REDUCE trial) was to evaluate 
whether this multicomponent intervention was 
effective and safe at reducing prescribing of antibiotics 
when patients consult with RTIs, when delivered 
electronically into general practices over 12 months.
Methods
Study design and participants
The study was an open label, two arm, parallel group, 
cluster randomised trial with general practices as the 
unit of allocation. The target population for this trial 
was the general population registered with general 
practices in the United Kingdom, including England, 
Scotland, Wales, and Northern Ireland. The trial was 
conducted by use of the anonymised electronic health 
records of general practices contributing to the UK 
Clinical Practice Research Datalink (CPRD). The CPRD 
is one of the world’s largest databases of primary care 
electronic health records, and it includes data updated 
monthly from general practices throughout the UK. 
CPRD data have been extensively evaluated and 
employed for epidemiological14 and interventional 
research.15 General practices contributing to CPRD 
were invited to participate in the study from September 
2015. General practices were included in the trial 
if they were actively contributing data to CPRD and 
consented to participation in the trial. Data for all 
registered patients from trial practices in CPRD were 
included; there were no exclusion criteria.
The protocol was approved by the NHS London-
Dulwich research ethics committee (14/LO/1730) 
and by the CPRD independent scientific advisory 
committee (ISAC 14_130). Trial oversight was provided 
by independent trial steering and data monitoring 
committees. Each participating general practice gave 
written informed consent for participation. General 
practices were randomised between 11 November 
2015 and 9 August 2016, and final follow-up was on 
9 August 2017. The trial was stopped when the last 
general practices completed 12 months of follow-up. 
The study protocol has been reported previously,16 and 
the updated protocol including amendments to the 
sample size calculation and statistical analysis plan 
has been published online.
Randomised controlled trial
All patients registered at one of  participating general practices
Visual Abstract
Prescribing rate (≥ year olds) 114.7 115.5
The intervention resulted in moderate reductions of antibiotic 
prescribing overall and in adults aged  to , with no evidence 
that serious bacterial complications increased.
Prescribing rate (- year olds) 139.3 139.8
Prescribing rate (- year olds) 89.9 100.2
Summary
Population
©  BMJ Publishing group Ltd.Read the full article online: http://bit.ly/BMJabfeed
Outcomes
Comparison
Adjusted prescribing rate ratio   % CI
Antimicrobial stewardship
Effectiveness of electronically delivered
prescribing feedback and decision support 
on antibiotic use in primary care
Primary outcome
Rate of antibiotic prescriptions 
for respiratory tract infections
One antibiotic prescription avoided 
for every  patients aged -
Clinical significance
Antibiotic prescribing rate 
per  person years
Scale
582 675 Age <: .% Comorbidity: .%.% female
323 155
Antimicrobial stewardship intervention
Training webinar
Monthly prescribing reports
Decision support tools
259 520
Usual care
Control
0.75 to 0.950.84
0.82 to 1.120.96
0.79 to 1.180.97
Population numbers shown are “person years of follow-up”!
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Randomisation and masking
Cluster randomisation was used because intervention 
was delivered at the general practice level. CPRD staff 
(JS and KS) were responsible for recruiting practices 
to the trial and communicating allocations but had 
no access to the allocation procedure. Allocation to 
antimicrobial stewardship and usual care trial arms 
was done at King’s College London (MCG, ATP) by 
minimisation using the MINIM program,17 stratifying 
by region and by pre-trial fourths of antibiotic 
prescribing (as a proportion of RTI consultations with 
antibiotics prescribed). “Region” comprised Scotland; 
Wales; Northern Ireland; and, in England, North 
(including North East, North West, and Yorkshire 
and Humber), Midlands (including East and West 
Midlands), South and East (including East of England, 
South Central, and South East Coast), South West, and 
London. Because only two practices were recruited 
in the Midlands, this region was combined with 
North for analysis. General practices consented to 
participation over an extended recruitment period; 
they were allocated in six waves, which were combined 
for analysis into three periods (period 1, practices 
randomised in November 2015; period 2, January 
and February 2016; period 3, June to August 2016). 
One practice allocated to the intervention trial arm 
withdrew from CPRD before the intervention started 
and was excluded from further analysis because no 
data were available. Health professionals were not 
blinded to trial arm allocation.
Interventions
An intervention development study was conducted 
and is described in detail elsewhere.16 18 Development 
of the antimicrobial stewardship intervention drew 
on social cognitive theory19 and self determination 
theory,20 experience from development of a previous 
intervention,15 21 22 and qualitative interviews 
with 31 prescribers to refine prototype versions of 
interventions. The intervention comprised three 
elements that were delivered remotely into practices 
using electronic media (table 1). A six minute, pre-
recorded webinar introduced and provided brief 
training in use of the trial interventions. Antibiotic 
prescribing reports were prepared through analysis 
of CPRD electronic health records, which are updated 
monthly (supplementary figure 1). These reports were 
sent to each general practice by email, to present 
monthly updated feedback of data for counts of 
respiratory consultations and antibiotic prescriptions 
for that practice, in comparison with the preceding 
12 months. Data were not analysed at the individual 
prescriber level because this information is not 
consistently available within CPRD. 
Decision support tools were deployed remotely 
into existing practice software to provide patient 
information sheets and advice on the positive 
indications for antibiotic prescription during 
consultations for RTI (supplementary figure 2). 
Patient information sheets were provided for common 
colds and upper respiratory infections, sore throat, 
otitis media, sinusitis, and cough and bronchitis 
(supplementary figure 3). Separate sheets for children 
were provided for otitis media and cough and 
bronchitis. Recommendations for positive indications 
for antibiotic prescription followed NICE guidance 
(supplementary figure 4).6 Intervention materials 
were accessible to all prescribers in antimicrobial 
stewardship trial arm practices. General practices were 
asked to identify a general practitioner as a champion 
for the study, generally the research coordinator 
at the practice, who ensured that all prescribers at 
the practice were aware of the trial, learned how to 
use the decision support tools, and received copies 
of the antibiotic prescribing feedback reports each 
month. Practices were encouraged to discuss the 
webinar and antibiotic prescribing feedback reports at 
practice meetings. A more extensive description of the 
intervention is published elsewhere.18 There were no 
modifications during the course of the study. General 
practices randomised to usual care received no study 
interventions.
Outcomes
Outcomes for both trial arms of antimicrobial 
stewardship and usual care were evaluated by use of 
anonymised electronic health records of individual 
patients from CPRD. Consultations for self limiting 
RTIs were identified from medical codes for cough and 
bronchitis, otitis media, rhinosinusitis, sore throat, 
and common colds. Medical codes were drawn from the 
Read code classification (supplementary tables  6-7), 
which was in use in the UK at this time, including 
symptoms and medical diagnoses. Lower respiratory 
tract infections including “chest infections,” 
exacerbations of chronic bronchitis, and pneumonia 
were not included because they are subject to different 
treatment recommendations. Antibiotic prescriptions 
were identified from product codes for antibiotics 
included in the British National Formulary section 5.1. 
We determined whether antibiotics were prescribed on 
the same date as the RTI consultation. In order to focus 
on prescribing decisions at initial presentations for 
RTI, we excluded repeat consultations for RTI during 
the same episode using a 14 day time window. As 
sensitivity analyses, we evaluated whether estimates 
differed for a 10 day window or no time window. 
The primary outcome measure was the rate of 
antibiotic prescribing for RTI per 1000 patient years over 
the 12 month intervention period. Secondary outcome 
measures were the proportion of RTI consultations 
with antibiotics prescribed, the consultation rate for 
RTI per 1000 patient years, antibiotic prescribing for 
subgroups of RTI, and total antibiotic prescribing for 
all indications. Safety outcomes were identified by 
the data monitoring committee as new occurrences 
of a wide range of serious bacterial complications 
including pneumonia, peritonsillar abscess, 
mastoiditis, intracranial abscess, empyema, scarlet 
fever, pyelonephritis, septic arthritis, osteomyelitis, 
meningitis, toxic shock syndrome and septicaemia, 
and Lemierre’s syndrome. Interim analyses of safety 
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outcomes were presented to the data monitoring 
committee in October 2016 and April 2017. The 
comorbidity status of patients consulting with RTI was 
classified as present or absent based on “seasonal flu 
at-risk” status including diagnoses of significant heart, 
lung, renal, liver, or neuromuscular disease, as well as 
cystic fibrosis, diabetes, and immunosuppression or 
immunosuppressive treatment.23
Statistical analysis
The primary outcome for the trial was the rate of 
antibiotic prescriptions for RTI per 1000 patient years. 
The sample size calculation was based on analysis of 
outcomes aggregated to cluster level; it was informed 
by data from our previous trial15 in CPRD. The 
distribution of general practices’ prescribing rates of 
antibiotics had a mean 111.9 (standard deviation 39.8) 
prescriptions per 1000 patient years, with a correlation 
coefficient of 0.82 between prescribing in the baseline 
and intervention periods. We initially aimed to recruit 
120 CPRD general practices. Based on analysis of 
covariance, this number would have enabled the 
study to detect an absolute reduction in antibiotic 
prescribing for RTI of 12 per 1000 registered patients. 
During the recruitment phase of the trial, this target 
was not achieved because of declining numbers of 
general practices using “Vision” software contributing 
to CPRD. An updated sample size calculation on 11 
July 2016 found that that a revised total of 80 practices 
would give 80% power (with α=0.05) to detect an 
absolute reduction in antibiotic prescribing rate of 15 
per 1000 patient years.
Individual level patient data for primary, secondary, 
and safety outcomes were analysed according to the 
intention-to-treat principle. The original protocol16 
proposed a general practice-level analysis, but this 
was amended in the statistical analysis plan, and 
approved by the CPRD independent scientific advisory 
committee, because attrition of practices during the 
trial and increased focus on safety outcomes7 required 
consideration of covariates at the level of individual 
patients, as well as consideration of temporal effects in 
an individual level analysis.
The trial dataset comprised full electronic health 
records data for all patients who consulted with RTI 
on one or more occasions during the trial baseline 
and intervention periods, together with denominator 
data for all patients registered at trial practices. For 
each registered patient, we evaluated the person 
time at risk during the 12 month intervention period 
of the trial. A random effects Poisson model was 
fitted using the “hglm” package in the R program,24 
with a random intercept for general practice and the 
log of person years as offset. The dependent variable 
was a count of antibiotic prescriptions. Covariates 
were trial arm, sex, age group, comorbidity status, 
region, study quarter, and baseline prescribing 
rate of antibiotics. The period of randomisation 
was included, as well as the interaction of period 
with the baseline prescribing rate. The baseline 
prescribing rate of antibiotics was included as an 
age standardised rate for each practice, using the 
European standard population for reference. For 
practices that withdrew during the intervention 
Table 1 | Summary of final intervention content and delivery. AMR=antimicrobial drug resistance; RTI=respiratory tract infection
Intervention component and content Delivery
Webinar
Professionally produced video narrated by a practising general practitioner in a general practice 
setting, summarising:
Webinar delivered through electronic link embedded in trial start letter
 Importance of antimicrobial drug resistance Webinar also delivered into practice system by proprietary software with 
active alerting
 Introduction to decision support tools General practitioners encouraged to present and discuss webinar in 
practice meetings
  Introduction to antibiotic prescribing reports, including reduced antibiotic prescribing and patient 
safety, and reduced antibiotic prescribing and patient satisfaction
—
Antibiotic prescribing reports
Monthly updated reports on antibiotic prescribing for RTI, including: Delivered by email to the general practitioner identified as champion for 
the trial at the practice
 Professionally designed template Requested to circulate prescribing reports to all prescribers at the 
practice
 Data for number of RTI consultations and antibiotic prescriptions for RTI aggregated by month General practitioners encouraged to discuss prescribing reports in 
practice meetings
 Automated calculation of estimates written into a template using a software program written in R Provided evidence of audit for professional appraisals
 Data presented as table and barchart in PDF document —
 Comparison with previous year at the same practice —
 Accompanying commentary and links to decision support tools —
Decision support tools
Professionally designed decision support tools, including: Delivered into general practice systems through proprietary software
  Printable patient information leaflets for cough and bronchitis, otitis media, sinusitis, sore throat, 
and common cold and upper respiratory tract infection
Activated during consultations when medical codes for RTI were entered 
into patient electronic records
 Versions for children with otitis media, and cough and bronchitis —
  Advice to patients and carers on expected duration of illness, expected course and lack of effect of 
antibiotics, recommendations for self care, and advice on appropriate reasons to seek help
—
  Summary for prescribers of the indications for which an antibiotic prescription is usually neces-
sary, based on national recommendations
—
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period, baseline time was included pro rata. Forest 
plots were constructed. We did a sensitivity analysis 
for the primary outcome by fitting an overdispersed 
Poisson model using the “dhglm” package in the R 
program.24
Data were visualised by calculating antibiotic 
prescribing rates for RTI by a single year of age 
and fitting smoothed curves using third degree 
polynomials. These empirical data were compared 
with estimates from a fully adjusted random effects 
Poisson model incorporating a third order polynomial 
term for age and the interaction with trial arm, with age 
15 years used as reference.
Safety outcomes were ascertained from CPRD 
clinical and referral files. The referral files include 
coded data for hospital referrals and discharge letters. 
We analysed safety outcomes adjusting for age group, 
sex, and comorbidity. A random effect for general 
practice was included for the most common outcome 
of pneumonia and for the composite, but this was 
omitted for the remaining outcomes.
Interaction terms were tested and prespecified 
subgroup analyses were conducted. The statistical 
analysis plan included prespecified subgroup analyses 
by age group, sex, comorbidity, region, type of 
infection, and baseline antibiotic prescribing fourth. 
Age group was categorised from 0 to 14 years, then in 
10 year bands, until 85 years and over. The subgroup 
effect was assessed statistically on this basis and the 
effect was summarised more simply in those aged 0-14 
years classed as children, those aged 15-84 years, and 
those aged 85 years and over.
Data on use of decision support tools was collected 
directly into the proprietary software used to deliver 
the tools. For each general practice, we estimated 
the proportion (%) of RTI consultations at which 
decision support tools were viewed, and we evaluated 
a linear trend for the primary outcome across fourths 
of decision support tool use adjusting for the same 
covariates.
Patient and public involvement
The trial procedure and proposed intervention were 
presented to a participation group of patients in 
primary care, and feedback and views were obtained 
on all aspects of the intervention including the 
way in which messages would appear on general 
practitioners’ screens, and information that would be 
presented to patients.
Results
Of 80 general practices recruited to the trial, one 
withdrew from CPRD before the start of intervention 
and the remaining 79 were included in the intention-
to-treat analysis (fig 1). The trial included general 
practices from throughout the UK (table 2), and the 
registered population included patients of all ages. 
RTI consultation and antibiotic prescribing rates were 
similar overall between trial arms but showed wide 
variation among practices (table 2). General practices 
at in the antimicrobial stewardship arm had slightly 
higher numbers of registered patients than the usual 
care arm, but the range of practice sizes was similar 
across both trial arms.
General practices (362 545 patients)
allocated to AMS trial arm
General practices (278 467 patients)
allocated to usual care trial arm
General practices (641 012 patients) recruited to the REDUCE trial and allocated
General practices (3.25 million patients) contributing to Clinical Practice Research Datalink at trial start
381
General practices (2.76 million patients) at trial end
329
80
38
Usual care general practices (32 573 patients)
migrated soware systems and were unable
to contribute data up to intervention end
42
General practices in usual care trial arm contribute to
analysis with 33 completing 12 months’ follow-up.
275 490 patients with 259 520
person years of follow-up
38
General practices in AMS trial arm contribute to
analysis with 35 completing 12 months’ follow-up.
348 158 patients with 323 155
person years of follow-up
41
5
General practice (14 387 patients)
migrated soware systems
before AMS start
1
AMS general practices (53 721 patients)
migrated soware systems and were unable
to contribute data up to AMS end
6
Fig 1 | Flowchart showing trial general practices and registered populations. Numbers of patients are those registered 
with practices and contributing data in the baseline period except where indicated. AMS=antimicrobial stewardship 
intervention
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Primary outcome
Figure 2 presents the results for analysis of the 
primary outcome. The adjusted rate ratio for antibiotic 
prescribing for RTI was 0.88 (95% confidence interval 
0.78 to 0.99, P=0.04). The antimicrobial stewardship 
trial arm had 31 907 antibiotic prescriptions for RTI 
during 323 155 patient years at 41 practices, with 
98.7 prescriptions per 1000 patient years. The usual 
care trial arm had 27 923 prescriptions during 259 520 
person years at 38 practices, with 107.6 prescriptions 
per 1000 patient years. Adjustment for covariates 
was pre-planned, before analysis, in order to improve 
the precision of estimated intervention effects. For 
comparison, the unadjusted rate ratio would have been 
0.89 (0.68 to 1.16). In an analysis of data aggregated 
to general practice level, the mean difference in the 
age standardised rate of antibiotic prescribing was 
−0.5 (95% confidence interval −8.2 to 7.2) antibiotic 
prescriptions per 1000 patient years. 
These imprecise estimates resulted from wide 
variations in antibiotic prescribing between general 
practices; the data appeared to be overdispersed with 
several extreme values. The coefficient of variation of 
general practice specific rates of antibiotic prescribing 
was 0.51. Adjusting for covariates reduced the 
standard error of the coefficient, which was largely 
accounted for by adjustment for practices’ antibiotic 
prescribing for RTI at baseline. In a sensitivity analysis, 
an overdispersed Poisson model gave an adjusted rate 
ratio of 0.86 (95% confidence interval 0.75 to 0.97), 
which confirmed conclusions. Sensitivity analyses, 
which compared the base case 14 day time window 
(for excluding secondary consultations) with either a 
10 day time window or no time window, showed that 
the effect estimate was not sensitive to whether a time 
window was used or its length (supplementary table 1).
Secondary outcomes
We saw insufficient evidence for a difference between 
trial arms for the consultation rate for self limiting 
respiratory infections (rate ratio 0.94, 95% confidence 
interval 0.86 to 1.03), proportion of consultations 
with antibiotics prescribed (where RTI consultations 
rather than person time represented the denominator; 
0.96, 0.89 to 1.03), and antibiotic prescribing for 
all indications (0.93, 0.83 to 1.04; supplementary 
Table 2 | Characteristics of trial general practices and patient populations at baseline
Trial arm
Antimicrobial stewardship Usual care
General practices
Number 41 38
Region
 London 4 (9.8) 3 (7.9)
 Midlands and North England 4 (9.8) 4 (10.5)
 Northern Ireland 4 (9.8) 5 (13.2)
 Scotland 10 (24.4) 9 (23.7)
 South and East England 8 (19.5) 6 (15.8)
 South West England 3 (7.3) 4 (10.5)
 Wales 8 (19.5) 7 (18.4)
Period of randomisation
 November 2015 7 (17.1) 11 (28.9)
 January-February 2016 18 (43.9) 13 (34.2)
 June-August 2016 16 (39.0) 14 (36.8)
Practice list size (median (range)) 8936 (1086-18 425) 6777 (2530-18 557)
Total registered patients
Number 348 158 278 467
Age group (years)
 <15 55 577 (16.0) 47 509 (17.1)
 15-24 40 544 (11.6) 30 610 (11.0)
 25-34 45 545 (13.1) 37 444 (13.4)
 35-44 46 288 (13.3) 38 766 (13.9)
 45-54 52 447 (15.1) 41 507 (14.9)
 55-64 42 275 (12.1) 33 769 (12.1)
 65-74 35 746 (10.3) 26 760 (9.6)
 75-84 20 919 (6.0) 15 264 (5.5)
 ≥85 8817 (2.5) 6838 (2.5)
Sex
 Male 173 383 (49.8) 138 588 (49.8)
 Female 174 775 (50.2) 139 879 (50.2)
Comorbidity
 No 288 594 (82.9) 238 106 (85.5)
 Yes 59 564 (17.1) 40 361 (14.5)
Antibiotic prescribing rate (No per 1000 patient years; median (range))* 108 (4-244) 114 (20-266)
RTI consultation rate (No per 1000 patient years; median (range))* 261 (11-454) 261 (76-526)
Proportion of RTI consultations with antibiotics prescribed (%; median (range))* 43 (12-64) 43 (24-78)
Data are number (% of column total) unless indicated otherwise. RTI=respiratory tract infection. 
*Numbers were age standardised, using the European standard population for reference.
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table 2).16 During the intervention period, 185 924 
antibiotic prescriptions were made in the AMS trial 
arm and 150 539 prescriptions in the usual care trial 
arm (supplementary table 2).
Safety outcomes
Figure 3 presents numbers of serious bacterial 
complications by trial arm, together with a forest 
plot of rate ratios. We saw no evidence to suggest 
that bacterial infections were more frequent in the 
antimicrobial stewardship arm (rate ratio 0.92, 95% 
confidence interval 0.74 to 1.13) than in the usual care 
arm. The usual care arm had slightly more events of 
scarlet fever, and the antimicrobial stewardship arm 
had slightly more empyema events, but these were 
likely to be chance findings. The usual care arm had 
one case of Lemierre’s syndrome. We saw no evidence 
that the adjusted rate ratio varied by age group 
(χ2=1.228, df=8, P=0.99); the adjusted rate ratio was 
0.82 (0.44 to 1.51) for children and 0.99 (0.59 to 1.70) 
for people aged 85 years and older.
Subgroup analyses
Subgroup analyses by individual patient characteristics 
are shown in figure 2. Antibiotic prescribing was 
strongly associated with age (Wald test of the trial arm 
by age group interaction, χ2=65.5, df=8, P<0.001). 
Results of a prespecified subgroup analysis by age 
are shown in figure 2. We saw no evidence of an effect 
of intervention in children aged under 15 years (rate 
ratio 0.96, 95% confidence interval 0.82 to 1.12) or 
in people aged 85 years or older (0.97, 0.79 to 1.18). 
In the usual care trial arm, children accounted for 
6432 (23%) antibiotic prescriptions, while people 
aged 85 years and older accounted for 680 (2%). At 
intermediate ages, antibiotic prescribing was lower 
in the antimicrobial stewardship arm than in the 
usual care arm. We summarised effect modification 
by age by comparing effect measures in children, 
adults aged 15-84 years, and people aged 85 years 
and older (supplementary table 3). The intervention 
was associated with lower antibiotic prescribing for 
RTI in adults aged 15-84 years (0.84, 0.75 to 0.95). 
Based on the antibiotic prescribing rate for adults aged 
15-84 years in the usual care arm of 100.2 per 1000 
patient years, the absolute risk reduction was 16.0 
(5.0 to 25.1) antibiotic prescriptions per 1000 patient 
years. This is equivalent to the saving of one antibiotic 
prescription per year for every 62 registered patients 
(95% confidence interval 40 to 200) aged 15-84 years.
Figure 4 presents empirical trial data for antibiotic 
prescribing rates for RTI by single year of age. Fitted 
polynomial curves suggest that from the late teens to 
the early eighties, antibiotic prescribing for RTI was 
lower in the intervention trial arm, but there was no 
evidence of reduced antibiotic prescribing in children 
or very old people. Estimates from the fully adjusted 
regression model (fig 4) show the same pattern of 
effect with evidence of reduced prescribing in the 
intervention trial arm from the late teens to early 
eighties. Data were relatively sparse at very advanced 
ages, with fewer than 500 patient years’ follow-up at 
any single year of age over 90 years.
There was no evidence that the effect of intervention 
might differ by sex (χ2=1.264, df=1, P=0.26) or 
comorbidity (χ2=2.424, df=1, P=0.12). Analysis by 
Total
Age group (years)
  <15
  15−24
  25−34
  35−44
  45−54
  55−64
  65−74
  75−84
  ≥85
Sex
  Male
  Female
Comorbidity
  Absent
  Present
0.88 (0.78 to 0.99)
0.96 (0.82 to 1.12)
0.92 (0.81 to 1.04)
0.90 (0.79 to 1.02)
0.90 (0.79 to 1.03)
0.84 (0.73 to 0.96)
0.79 (0.69 to 0.91)
0.80 (0.70 to 0.91)
0.79 (0.69 to 0.91)
0.97 (0.79 to 1.18)
0.90 (0.80 to 1.01)
0.87 (0.77 to 0.98)
0.86 (0.74 to 1.00)
0.88 (0.79 to 0.99)
0.6 0.8 1.21.0
Covariate Rate ratio
(95% CI)
Rate ratio
(95% CI)
98.7
139.3
83.6
78.2
78.6
79.9
99.6
113.8
121.7
114.7
80.0
117.3
60.9
287.0
AMS
107.6
139.8
94.3
86.4
83.4
86.0
112.8
132.8
146.1
115.5
87.7
127.3
72.5
314.7
Usual care
Antibiotic prescribing rate
per 1000 patient years for RTI
Fig 2 | Effect of antimicrobial stewardship or usual care on primary outcome of antibiotic 
prescribing rate for self limiting respiratory tract infection. Estimates adjusted for 
random effect of general practice and covariates including sex, age group, comorbidity, 
region, quarter in study, practice specific rate at baseline, and interaction with period 
of randomisation. AMS=antimicrobial stewardship intervention; RTI=respiratory tract 
infections
Person years
Pneumonia
Pyelonephritis
Scarlet fever
Peritonsillar abscess
Septic arthritis
Osteomyelitis
Mastoiditis
Meningitis
Empyema
Intracranial abscess
Septicaemia
All
0.93 (0.70 to 1.24)
1.01 (0.77 to 1.34)
0.70 (0.50 to 0.99)
0.90 (0.59 to 1.35)
0.69 (0.32 to 1.47)
1.38 (0.66 to 2.86)
0.79 (0.28 to 2.25)
1.16 (0.41 to 3.27)
2.43 (0.79 to 7.46)
0.27 (0.03 to 2.61)
1.27 (0.37 to 4.34)
0.92 (0.74 to 1.13)
0.1 101
Condition Rate ratio
(95% CI)
Rate ratio
(95% CI)
323 155
367
115
60
49
13
21
7
9
13
1
7
662
AMS
259 520
299
84
72
42
14
11
7
6
4
3
4
546
Usual care
Fig 3 | Forest plot showing rate ratios (95% confidence interval) of safety outcomes in 
antimicrobial stewardship trial arm compared with usual care trial arm as reference. 
Data are frequencies except where indicated. Estimates were from a Poisson model 
adjusted for age group, sex, and comorbidity. Analyses for pneumonia and combined 
outcome were adjusted for random effect of general practice. One case of Lemierre’s 
syndrome in the usual care arm not shown. AMS=antimicrobial stewardship 
intervention
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subgroup of practice level covariates (region and 
baseline antibiotic prescribing fourth) showed no 
consistent pattern of association (supplementary 
table  4). We saw no evidence of association of 
intervention with antibiotic prescribing for any 
subgroup of RTI separately (supplementary table 5).
Process evaluation
We evaluated the primary outcome measure in 
relation to the level of use of decision support tools at 
practices in the antimicrobial stewardship trial arm. In 
the lowest fourth of use, decision support tools were 
viewed at fewer than 1% of RTI consultations but up 
to 28% in the fourth with the highest use (table  3). 
We saw evidence of a linear trend in the primary 
outcome across fourths of decision support tool use, 
with relative risk reduction of 3.4% per fourth (95% 
confidence interval 0.1% to 6.5%). This association 
appeared to be stronger for adults, with no evidence 
of association for children or people aged 85 or older 
(table 3). In the intervention period, the number of 
patient information leaflets printed per practice ranged 
from zero to 555, with median 54 (interquartile range 
7-97) leaflets printed per practice.
Discussions
Principal findings of the study
In a nationwide sample of general practices, a low 
cost, remotely delivered intervention using electronic 
health records data to provide antibiotic prescribing 
feedback reporting, together with computer delivered 
decision support tools, was effective at reducing 
antibiotic prescribing for self limiting RTIs to adults. 
The reduction in antibiotic use was greater at practices 
that used the trial intervention (decision support 
tools) more frequently. We saw no evidence that 
the intervention was effective at reducing antibiotic 
prescribing to children or people aged 85 years or older. 
The trial decision support tools specifically addressed 
common diagnostic concerns in children, including 
otitis media and cough and bronchitis, but prescribing 
to the youngest and oldest age groups could be more 
difficult to modify because safety concerns might be 
more salient at these ages.25 Conversely, unnecessary 
prescribing might be more frequent, and possibly 
more readily modified, at intermediate ages.26 The 
intervention was delivered at low cost. The budget 
for the trial, including research costs, was £533 580 
(€603 316; $687 802), which implies that the research 
and intervention were delivered for less than £1 
per patient year. The marginal cost of extending 
the intervention to more practices might be lower. 
Additional analysis found no evidence that overall 
costs of healthcare use were different in the AMS and 
usual care trial arms.18
The trial was designed with the antibiotic prescribing 
rate as the primary outcome because such prescribing 
can influence subsequent consultation patterns for 
Table 3 | Association of antibiotic prescribing rate for self limiting respiratory tract infection with use of decision support tools, by age group
Fourth of decision support tool use RTI consultations with DST viewed (%)
Antibiotic prescribing for respiratory tract infection/No of person years)
All Age 0-14 years Age 15-84 years Age ≥85 years
Usual care trial arm — 27 923/259 519.7 6432/46 019.6 20 811/207 611.4 680/5888.7
Lowest fourth 0 to 0.6 7190/85 805.1 1932/15 699.9 5089/68 220.1 169/1885.1
Second fourth 0.6 to 2.9 7765/74 868.3 1706/12 009.4 5837/60 825.5 222/2033.4
Third fourth 2.9 to 6.1 10 647/91 986.9 2339/15 233.4 7957/74 735.5 351/2018.0
Highest fourth 6.1 to 27.6 6305/70 495.1 1520/10 883.6 4668/58 060.1 117/1551.3
Relative risk reduction (%; 95% CI) per fourth 
increase in decision support tools*†
— 3.4 (0.1 to 6.5) 1.60 (−2.7 to 5.7) 4.3 (1.1 to 7.5) 1.0 (−4.6 to 6.3)
P value — 0.04 — — —
*Adjusted for random effect of general practice and fixed effects of sex, age group, comorbidity, region, quarter in study, practice specific rate at baseline, and interaction with period.
†Rate ratio represents the reduction in antibiotic prescribing per fourth increase in decision support tools.
Trial data
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Fig 4 | Comparison of antibiotic prescribing by single year of age for antimicrobial 
stewardship and usual care trial arms. Top panel: antibiotic prescribing rates per 1000 
patient years by single year of age, with fitted third order polynomial curve. The y axis 
uses a log scale. Bottom panel: log relative risk estimates from random effects Poisson 
model using age 15 years for reference; log relative risk estimates were adjusted for 
random effect of general practice and covariates including sex, age group, comorbidity, 
region, quarter in study, practice specific rate at baseline, and interaction with period 
of randomisation. AMS=antimicrobial stewardship intervention; RTI=respiratory tract 
infections
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respiratory illness. Patients are more likely to consult 
for RTI if they have been prescribed antibiotics 
recently.5 The effect of antimicrobial stewardship 
interventions on prescribing could be partly mediated 
by changes in RTI consultation patterns. Consequently, 
measures such as the proportion of RTI consultations 
with antibiotics prescribed could underestimate 
intervention effects. This study did not find sufficient 
evidence that the proportion of RTI consultations with 
antibiotics prescribed or the rate of RTI consultations 
were reduced by the antimicrobial stewardship 
intervention, but both measures tended to be slightly 
lower in the antimicrobial stewardship arm than in the 
usual care arm.
The study did not find evidence that the intervention 
might influence the total use of antibiotics at these 
practices. Antibiotic prescriptions that are clearly 
associated with a documented RTI represented 
a substantial proportion of prescriptions, but 
nevertheless a minority consistent with another recent 
study,27 because an appreciable proportion of antibiotic 
prescriptions are associated with non-specific medical 
codes or with no code recorded. Future studies 
should therefore address a wider range of prescribing 
indications as well as issues of coding quality. We also 
note that only about a quarter of eligible general practices 
agreed to participate in the trial, and if this level of 
uptake were to be replicated in any future intervention 
rollout, then any possible population benefits would be 
proportionately smaller.28 The trial continued over 12 
months and it did not provide evidence concerning any 
possible longer term outcomes. The trial intervention 
did not address selection of different antimicrobial 
drugs, though nationally there has been a substantial 
reduction in prescribing of broad spectrum antibiotics 
in recent years.29
Analysis of electronic health records data for serious 
bacterial complications as safety outcomes showed 
no difference between trial arms. This study was 
considerably larger than most previous studies, but 
was nevertheless not designed to provide conclusive 
evidence concerning the safety of reducing antibiotic 
prescribing. Even a much larger study might have 
limited power to evaluate less frequent safety 
outcomes or vulnerable subgroups with precision.7 
The confidence intervals for several individual 
diagnoses including meningitis, empyema, and sepsis 
were wide because these outcomes are infrequent but 
nevertheless could have a high impact on affected 
individuals. Outcomes were ascertained from Read 
codes recorded in primary care electronic records. 
Additional information might have been obtained 
through linked hospital records (Hospital Episodes 
Statistics), but these data were not available for all trial 
practices. Safety outcomes were evaluated during the 
12 month intervention period, but some safety events 
might take longer to become apparent.
Strengths and limitations of study
The trial was conducted in the context of national 
efforts to reduce unnecessary antibiotic prescribing 
in primary care that might have affected both trial 
arms with possible underestimation of intervention 
effects. Trial general practices represented all parts 
of the UK, but CPRD general practices in Scotland, 
Wales, and Northern Ireland were more likely to agree 
to participate in the trial than practices in England. 
General practices that agreed to take part might have 
been more motivated to reduce antibiotic prescribing. 
It is known that participation in research studies 
might cause individuals to alter their behaviour.30 
Prescribing feedback delivered to the intervention trial 
arm might have contributed to heightened awareness 
of research participation and could have influenced 
antibiotic prescribing patterns; smaller changes might 
be observed if prescribing feedback is used outside of 
the context of a research study. 
The number of practices included was smaller than 
originally intended and several practices were unable 
to continue with the trial because they transferred to a 
different practice information system. In our previous 
study, allocation was stratified by practice list size 
and region,15 but the present trial’s allocation was 
stratified by antibiotic prescribing fourth and region. 
Consequently, there was good balance between trial 
arms for baseline antibiotic prescribing for RTI, but 
trial arms were less well balanced with respect to 
practice list sizes. However, the range of practice list 
sizes was similar in both trial arms. 
We saw wide variation in antibiotic prescribing 
for RTI between different general practices in both 
trial arms, which is consistent with data that we and 
others have reported previously.2 31 Consequently, the 
primary measure of effect was estimated imprecisely 
and neither a smaller effect nor a larger effect can be 
excluded. Based on subgroup analysis, we caution 
that the intervention appeared to be effective in 
adults but might not have an effect on prescribing to 
children or people aged 85 and older. We acknowledge 
that evaluation of multiple subgroup analyses might 
lead to false positive interpretations. However, our 
interpretation was guided by interaction tests, which 
provided strong evidence that the intervention effect 
varied by age group but not by sex or comorbidity. We 
do not present P values within subgroups. 
We found from analysis of data captured by the 
intervention delivery software that use of decision 
support tools was associated with effect size, which 
adds evidence of a causal association. Decision support 
tools were used at a minority of consultations but it is 
possible that learning from the tools might be applied 
in consultations in which they were not viewed. 
Decision support tools were necessarily triggered when 
prescribers entered medical codes into the practice 
system. Some general practitioners might record data 
after the end of the consultation, or might rely on free text 
entries, reducing the immediacy of this component of 
the intervention, this post-consultation exposure might 
contribute to the effect of the intervention over time. 
All prescribers also received antibiotic prescribing 
reports but we were not able to determine whether 
all prescribers read these each month. There is likely 
 o
n
 25 February 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l236 on 12 February 2019. Downloaded from 
RESEARCH
10 doi: 10.1136/bmj.l236 | BMJ 2019;364:l236 | the bmj
to have been variation among prescribers within 
practices, but we did not have consistent data for 
the prescriber level and no information concerning 
prescriber characteristics. We analysed data for 
antibiotic prescriptions issued by trial general 
practices. Patients might have received antibiotic 
prescriptions at consultations with walk-in centres 
and out-of-hours or emergency services, and these 
alternative patterns of antibiotic use might differ 
between trial arms. Additional data sources will be 
needed to evaluate this possibility. Altered diagnostic 
code selection might have occurred in order to justify 
antibiotic prescriptions,32 so we included both 
symptoms and diagnosis codes to limit this. Safety 
outcomes were ascertained from medical codes in 
primary care records and we were not aware of whether 
any confirmatory tests might have been performed. 
There was necessarily no blinding of general practice 
staff to the intervention.
Comparison with other studies
Previous studies of audit and feedback interventions 
across a range of indications show that these often 
have only small effects,33 although some studies report 
larger effects.34 Roshanov and colleagues33 found that 
feedback interventions that provide advice to patients 
as well as physicians are associated with greater chance 
of success. This was exemplified in the REDUCE trial’s 
decision support tools, which offered patient information 
leaflets that could be viewed online or printed, as well 
as offering advice to physicians on the recognised 
indications for giving an antibiotic prescription. 
Gjelstad and colleagues35 reported a comparable 
effect from face-to-face delivery of feedback and 
guideline recommendations in a study from Norway. 
A recent trial reported on the outcome of quarterly 
feedback on antibiotic prescribing over two years 
among 2900 Swiss physicians.36 Over the first and 
second years of the trial, there was no difference in 
prescribing to all patients but there was evidence 
of reduced prescribing to adults aged 19-65 years 
that was not consistently observed over time. The 
feedback used by Hemkens and colleagues36 was 
less immediate, being provided quarterly rather than 
monthly. Additionally, Switzerland already has low 
antibiotic prescribing rates.37
Hallsworth and colleagues38 reported a reduction in 
antibiotic use following social norm feedback in a study 
focused on high prescribing general practices. A study 
of dental practices in Scotland found that feedback of 
past antibiotic prescription data was associated with 
a 5.7% relative reduction in antibiotic prescribing 
over 12 months.39 Audit and feedback has also been 
used successfully to reduce other forms of high risk 
prescribing in primary care.40 However, purposely 
designed interventions might be more effective for 
prescribing to children.41
Conclusions and policy implications
In this cluster randomised trial, an antimicrobial 
stewardship intervention that was delivered 
remotely into practices and integrated into 
routine care delivery was associated with a 12% 
reduction in antibiotic prescriptions for RTI overall, 
with no evidence of increased serious bacterial 
complications. Although the absolute impact is 
moderate, it is likely to be important for public 
health in the drive to reduce antibiotic prescribing 
and the risks of antimicrobial resistance. We 
caution that the intervention might not be effective 
at reducing antibiotic use for children or people 
aged 85 or older. Interventions using data from 
electronic health records might be used to promote 
antimicrobial stewardship in primary care and might 
be readily scaled up. The needs of very young or 
old patients need specific consideration. Our trial 
results also suggest the need for further research 
into the safety of reduced prescribing.
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